THE INFLUENCE OF THE ATHYMIC MUTATION NUDE ON THE COMPONENTS OF THE CIRCADIAN-RHYTHM OF ACTIVITY IN MICE

被引：1

作者：

BEAU, J

LEVI, F

MOTTA, R

机构：

[1] Genetique, Neurogénétique et Comportement, URA 1294 C.N.R.S., 75270, Paris, Cedex

[2] Chronobiologie-Chronopharmacologie-Cancer, SDI 6212 C.N.R.S., Hǒpital Paul Brousse, 94800, Villejuif

[3] etique sur les Modéles Animaux, UPS 71 C.N.R.S., 94802, Villejuif

来源：

CHRONOBIOLOGY INTERNATIONAL | 1990年 / 7卷 / 5-6期

关键词：

MICE; THYMUS; NUDE; CIRCADIAN RHYTHMS; GENETICS;

D O I：

10.3109/07420529009059147

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The mutation known as nude brings about the lack of a thymus gland in mice. This immuno-deficiency makes it possible to graft normally unaccepted, human cancerous tumors onto the mouse. Consequently, this animal is frequently used as a model for evaluating anti-cancer therapies. The effect of this mutation on biological rhythms constitutes a necessary step before using this model for cancer chronotherapy research. We evaluated the circadian and ultradian components of the restactivity cycle in the following strains of mice: C57BL/6 with homozygous nu/nu, heterozygous nu/+, thymectomised +/+, and sham-operated +/+. The amount of activity was reduced in nu/nu as compared to the other groups. Nonetheless, neither the nude mutation nor thymectomy yielded any notable change in the circadian rhythm of activity.

引用

页码：371 / 376

页数：6

共 20 条

[1]

Flannegan S.P., Nude, a new hairless gene with pleiotropic effects in the mouse, Gen Res, 8, pp. 295-309, (1966)

[2]

Pantelouris E.M., Lintern-Moore S., Physiological studies in the nude mouse, The Nude Mouse in Experimental and Clinical Research, (1978)

[3]

Ruitenberg E.J., Berkvens J.M., A morphological study of the endocrine system in congenitallyathymic (nude) mice, The Nude Mouse in Experimental and Clinical Research, (1978)

[4]

Ohsawa N., Matsuzaki F., Esaki K., Namura T., Endocrine functions of the nude mouse, The Nude Mouse in Experimental and Clinical Research, (1978)

[5]

Levi F., Hrushesky W., Blomquist J., Lakatua D., Haus E., Halberg F., Kennedy B.J., Reduction of cis-diamnisnedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing, Cancer Res, 42, pp. 950-955, (1982)

[6]

Boughattas N., Levi F., Fournier C., Lemoigne G., Roulon A., Hecquit B., Mathe G., Reinberg A., Circadian rhythms in toxicities and tissue uptake of oxaliplatin in mice, Cancer Res, 49, pp. 3362-3368, (1989)

[7]

Mormont M.C., Boughattas N., Levi F., Mechanisms of circadian rhythms in the toxicity and efficacy of anticancer drugs: relevance for the development of new analogs, Cellular and Biochemical Aspects of Chronopharmajcology, pp. 395-437, (1989)

[8]

Hrushesky W., Circadian timing of cancer chemotherapy, Science, 228, pp. 73-75, (1985)

[9]

Levi F., Bevanides M., Chevelle C., Et al., Chemotherapy of advanced cancer with 4′ tetrahydropyranyl doxorubicin (THP and cisplatin: a phase II trial with an evaluation of circadian timing and dose-intensity, J Clin Oncol, 8, pp. 705-714, (1990)

[10]

Foster M.L., Small J.D., Fox J.G., The Mouse in Biomedical Research, 1, (1981)

← 1 2 →